| Date Filed | Type | Description |
| 10/03/2023 |
4
| Mehra Uneek (See Remarks) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Granted 229,634 options to buy
@ $12.73, valued at
$2.9M
|
|
| 09/26/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 08/16/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 06/12/2023 |
4
| Bizily Scott (Chief Legal and HR Officer) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Sold 3,750 shares
@ $20.85, valued at
$78.2k
Exercised 3,750 options to buy
@ $8.04, valued at
$30.2k
|
|
| 06/06/2023 |
4
| Bizily Scott (Chief Legal and HR Officer) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Sold 2,247 shares
@ $18.3103, valued at
$41.1k
Exercised 1,875 options to buy
@ $6.49, valued at
$12.2k
|
|
| 05/25/2023 |
4
| MILLIGAN JOHN F (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Granted 33,750 options to buy
@ $17.98, valued at
$606.8k
|
|
| 05/25/2023 |
4
| Tomasello Shawn (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Granted 22,500 options to buy
@ $17.98, valued at
$404.6k
|
|
| 05/25/2023 |
4
| Miller-Rich Nancy (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Granted 22,500 options to buy
@ $17.98, valued at
$404.6k
|
|
| 05/25/2023 |
4
| THEUER CHARLES (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Granted 22,500 options to buy
@ $17.98, valued at
$404.6k
|
|
| 05/25/2023 |
4
| GRAY SUSANNAH (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Granted 22,500 options to buy
@ $17.98, valued at
$404.6k
|
|
| 05/25/2023 |
4
| Chacko Jacob (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Granted 22,500 options to buy
@ $17.98, valued at
$404.6k
|
|
| 05/25/2023 |
4
| Kasahara Noriyuki (Director) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Granted 22,500 options to buy
@ $17.98, valued at
$404.6k
|
|
| 05/25/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/16/2023 |
4
| Moretti August J (CFO) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Exercised 3,000 options to buy
@ $9.41, valued at
$28.2k
|
|
| 05/11/2023 |
4
| VIKING GLOBAL INVESTORS LP (10% Owner) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Bought 850,000 shares
@ $16, valued at
$13.6M
|
|
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/04/2023 |
4
| Kirn David (CEO) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Gifted 600,000 shares
@ $0
Gifted 600,000 shares
@ $0 |
|
| 05/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/03/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/05/2023 |
3
| Kim Robert Young (Chief Medical Officer) has filed a Form 3 on 4D Molecular Therapeutics, Inc. |
| 03/15/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
8-K
| Quarterly results |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/23/2023 |
4
| Kirn David (CEO) has filed a Form 4 on 4D Molecular Therapeutics, Inc.|
Txns:
| Sold 17,090 shares
@ $20.9314, valued at
$357.7k
Sold 907 shares
@ $21.4897, valued at
$19.5k
Sold 16,449 shares
@ $20.224, valued at
$332.7k
|
|
|